1995

Journal of Cardiopulmonary Rehabilitation Author Index

AACVPR Outcomes Committee, 394
Abraira C, 97
Ades PA, 14, 394
Ainsworth BE, 107
Allan R, 39
Amodio G, 65

Ballor DL, 14
Bernstein L, 39
Bickford LS, 406
Bishop PA, 34
Blumenthal JA, 431
Breslin EH, 25
Brown CS, 122
Bryant CX, 134

Cameron JL, 269
Chapman J, 424
Clark B, 277
Clark BA, 257
Clark, LT, 65
Coleman RE, 431
Conerly MD, 34
Conlin NC, 216
Cooper RS, 97
Cupples SA, 412

Darcy F, 186
Dech Z, 143
Deshotels A, 143
Dion W, 209
Dornan J, 424
Dressendorfer RH, 269
Dugan D, 130
Dwyer J, 114

Ellis L, 34
Elnaggar A, 277
Emery CF, 394, 420
Emmett JD, 19

Fardy PS, 65
Fernhall B, 225
Fischer A, 114
Fitzgerald H, 186
Forsyth G, 209
Foster C, 209
Franklin BA, 269
Frasure-Smith N, 103
Frid DJ, 394, 431

Gardner AW, 134
Goble AJ, 186
Gordon NF, 193
Gordon S, 269
Gottlieb SH, 122
Greenwood J, 39
Grevenow P, 209

Hambrecht R, 47
Hansen M, 209
Hanson MW, 431
Hare DL, 186
Harvey-Berino J, 14
Hickey CM, 122
Hiser E, 179, 418
Hodgkin JE, 406
Hurster MH, 65

Jacobs DR, 107
Jairath N, 424
Jiang W, 431

Kälberer B, 47
Kavanagh T, 288
Kübler W, 47

LaFontaine T, 262
Lamont LS, 183
Laubach CA, 257
Laubach CA, Jr, 216
Laughlin J, 209
Lavie CJ, 439
Leon AS, 107
Levine S, 277
Loose MS, 225

Magel JR, 65
Maki KC, 97
Mansfield ER, 34
Marburger C, 47
Martin A, 39
McConnell TR, 216
McConnell TR, 257
McCully KK, 283
McDermott KJ, 65
McFarland LD, 122
McInturff SL, 406
Menapace FJ, 216
Mertens D, 288
Milani RV, 439
Miller NH, 394
Monroe DA, 130

Morris JJ, 431

Niebauer J, 47
Normandin E, 277

O'Connor C, 431
Oldenburg B, 39
Oldridge NB, 9
Oldridge NB, 209

Pashkow P, 394
Peske G, 277, 394
Phillips BG, 431

Planchock N, 143
Plichta C, 209
Posner JD, 283
Prevost S, 143
Pulmonary Clinical Competencies Working Group:
Southard DR, 173,
Cahalin LP, 173,
Carlin BW, 173,
Cales M, 173,
McCleord VK, 173,
Morris K, 173,
Normandin EA, 173,
Reardon J, 173,
Ries AL, 173,
Sciaky AJ, 173
The Pulmonary Rehabilitation Committee Tri-State Society for Cardiovascular and Pulmonary Rehabilition, 197

Qureshi S, 288

Rabas S, 209
Race E, 186
Reardon JZ, 277, 394
Richardson MT, 107
Ryan KP, 197

Sadowsky S, 114
Salerno T, 424
Schlierf G, 47
Schiffert JH, 394
Schmidt DH, 209
Schuler G, 47
Scott CB, 193
Serfass R,107
Sharkey RE, 209
Shaw CE, 283
Shephard RJ, 288
Skinner JS, 134
Smith JF, 34
Smith LK, 134
Southard D, 394
Stewart KJ, 122

Timmis GC, 269
Trahan KJ, 269
Trauner MA, 431

Walker R, 130
Waugh RA, 431
Weinhofer JJ, 122
Weisel R, 424
Weiser PC, 197
White REC, 65

ZuWallack RL, 277, 394

1995

Journal of Cardiopulmonary Rehabilitation Subject Index

Adherence, cardiac and pulmonary rehabilitation and, 420
Adolescent, minority, health promotion and, 65
Aerobic exercise, chronic obstructive pulmonary disease and, 130
Aerobics stepper, portable, 81
Airflow obstruction
 breathlessness and, 236
 estimation of ventilatory reserve by stair climbing and, 76
Alcohol, progression of coronary artery disease and, 47
Ambulatory blood pressure monitor, 241, 306
Ambulatory Blood Pressure Report Management System for Windows, 158
Anaerobic threshold (AT)
 arterial lactate, hyperoxic gas and, 114
 determination, theoretical basis, 193
 gas exchange in heart disease and, 257
Aortic valve replacement (AVR), oxygen uptake and, exercise training and, 424
Arterial lactate breakpoint, hyperoxic gas and, 114
Aspirin, for myocardial infarction,cost-effectiveness per life year gained, 9
AT. *See* Anaerobic threshold
Atherosclerosis
 environmental tobacco smoke and, 233
 multiple risk factor reduction and, 74
 progression, stabilization, and regression, lipid management and, 262
Athlete's heart, 78
AVR. *See* Aortic valve replacement

Back rehabilitation machine, 305
Beano, 457
Beta-blocking agents, protein metabolism and resting energy expenditure and, 183
Blood pressure
 cardiac rehabilitation and, 394
 preadolescent children and, physical fitness, physical activity, fatness and, 122
 responses in the cold, 19
 responses at submaximal exercise, 19
 systolic, responses at rest, 19
Body weight, maintaining, daily fat gram goals and, 14
Book Reviews, 78, 154, 237, 301, 450
Breathing retraining, chronic obstructive pulmonary disease and, 25
Breathlessness. *See* also Dyspnea
 chronic airflow obstruction and, 236

CAD. *See* Coronary artery disease
Caltrac accelerometer, physical activity assessment and, 107
Captopril, for hypertension, cost-effectiveness per life year gained, 9
Carbohydrates, 418
Carbon dioxide output, gas exchange in heart disease and, 257
Cardiac Directions, 159
Cardiac output, progressive and constant work load after acute myocardial,infarction and, 216
Cardiac rehabilitation
 adherence and, 420
 based on group light exercise and discussion, 186
 behavioral and educational intervention, 39
 developing and managing programs, 78
 diabetes screening and, 97
 inpatient, 412
 lifestyle change programs and, 14
 nonpharmacologic treatment, 439
 outcome measurement, 394
 patient, pulmonary rehabilitation patient compared, 277
 perceptions of quality of life and, 143
  gender differences and, 225
 post-aortic/mitral valve surgery, 424
 post-infarction, exercise training and, 269
 time course of recovery, 209
 universal access and insurance coverage, 9
Cardiology Abstract Reviews, 73, 149, 232, 297
Cardiopulmonary exercise testing, chronic obstructive pulmonary disease and, 299
Cardiorespiratory fitness
 aerobic exercise and, 34
 exercise training and, 269
CardioSens/S, 158
Cardiovascular disease (CVD)
 exercise intensity prescription and, 193
 Mediterranean diet and, 179
 noninsulin-dependent diabetes mellitus and, 97
Cardiovascular Reviews, 445
Cateye Heartbeat Counter, 305
CHD. *See* Coronary heart disease
Cholesterol
 lowering in coronary heart disease patients, randomized trial, 232
 monounsaturated fats and, 179
 serum
  reduction with pravastatin, 149
  saphenous vein graft obstruction and, 297
Chronic airflow obstruction
 breathlessness and, 236
 estimation of ventilatory reserve by stair climbing and, 76
Chronic obstructive pulmonary disease (COPD)
 breathing retraining and, 25
 cardiopulmonary exercise testing and, 299
 exercise capacity in elderly and, pulmonary rehabilitation and, 447
 home rehabilitation program, quality of life and, 152
 maximal voluntary ventilation and, aerobic and upper body exercise and, 130
 quality of life and, short-form questionnaire and, 447
Claudication, stair climbing and, 134
Colestipol, for hypercholesterolemia, cost-effectiveness per life year gained, 9
Constant load work, after acute myocardial infarction, oxygen uptake and cardiac output and, 216
COPD. *See* Chronic obstructive pulmonary disease
COPD Knowledge Questionnaire, 130
Coronary artery bypass surgery
 behavioral and educational intervention following, controlled trial, 39
 coronary risk factors in women and, 445
 cost-effectiveness per life year gained, 9
 saphenous vein graft obstruction and, serum cholesterol and, 297
Coronary artery disease
Coronary artery disease (CAD)
 exercise and, 74
 heart rate and blood pressure responses in cold and, 19
 interventions, cost-effectiveness per life year gained, 9
 lipid lowering and, pravastatin and, 445
 multiple risk factor reduction and, 74
 myocardial ischemia and, physical fitness and, 431
 progression, physical exercise and low-fat diet and, 47
 progression, stabilization, and regression, lipid management and, 262
Coronary atherosclerosis, multiple risk factor reduction and, 74
Coronary disease, preventing heart attack and death and, 445
Coronary heart disease (CHD)
 detecting and treating, gender and, 143
 noninsulin-dependent diabetes mellitus and, 97
 obesity and, 14
 randomized trial of cholesterol lowering and, 232
Coronary vasomotion, endothelium-dependent in hypercholesterolemia, pravastatin and, 149

DB. *See* Diaphragmatic breathing
Depression, myocardial infarction and, 297
Diabetes screening, cardiac rehabilitation and, 97
Diaphragmatic breathing (DB), chronic obstructive pulmonary disease and, 25
Diet
  cardiac rehabilitation and, 394
  intervention following coronary artery bypass surgery and, 39
  lipid management and, 262
  progression of coronary artery disease and, 47
Dietary restriction, obesity in coronary patients and, 14
Dietary supplement, food enzyme, 457
Dual frequency stethoscope, 80
DynaPulse 5000A, 306
Dyspnea, pulmonary rehabilitation and, 394
  comprehensive outpatient, 76
Editorials, 9
Elderly
  exercise capacity and, pulmonary rehabilitation and, 447
  one repetition maximum assessment and, injury and, 283
Emergency cardiac unit, portable, 80
Energy expenditure, beta-blockers and, 183
Environmental tobacco smoke (ETS), arteriosclerotic plaque development and, 233
ETS. *See* Environmental tobacco smoke
Exercise
  cardiac rehabilitation and, 394
  chemical composition of low-density lipoprotein and, 150
  chronic obstructive pulmonary disease and, 130
  coronary artery disease patient and, 74
  intervention following coronary artery bypass surgery and, 39
  lipid management and, 262
  moderate intensity, fibrinolytic responses, 298
  progression of coronary artery disease and, 47
  pulmonary rehabilitation and, 394
  submaximal
    heart rate/blood pressure responses and, 19
    rate-pressure product and, 19
Exercise prescription, cardiovascular disease and, 193
Exercise rebounding, cardiorespiratory fitness and, 34
Exercise testing
  cardiac rehabilitation and, 186
  chronic obstructive pulmonary disease and, 299
  claudication patient and, 134
  suspected acute myocardial infarction and, 233
  transplanted heart and, 288
Exercise tolerance, cardiac rehabilitation and, 209
Exercise training
  oxygen uptake post-aortic/mitral valve surgery and, 424
  post-infarction cardiac rehabilitation and, 269

Fatness, preadolescent children and, 122
Fats, monounsaturated, effects on lipoproteins and triglycerides, 179
Food enzyme dietary supplement, 457
Four-Week Physical Activity History Questionnaire (FWH), 107
FWH. *See* Four-Week Physical Activity History Questionnaire

Gas exchange analysis, value in heart disease, 257
Gender
  perceptions of quality of life in cardiac rehabilitation and, 143, 225
  posthospital survival after acute myocardial infarction and, 150

HDL. *See* High-density lipoprotein
Health promotion, minority adolescent and, 65
Heart, transplanted, kinetics, 288
Heartbeat counter, 81, 305
Heart disease, gas exchange analysis and, 257
Heart rate
  responses in cold, 19
  responses at submaximal exercise, 19
  transplanted heart and, 288
High-density lipoprotein (HDL)
  cholesterol, 439
  monounsaturated fats and, 179
Hypercholesterolemia
  adolescent and, 65
  endothelium-dependent coronary vasomotion and, pravastatin and, 149
  interventions, cost-effectiveness per life year gained, 9
Hyperlipidemia, obesity and, 14
Hyperoxia, lactate concentration and gas exchange and, 114
Hypertension
  adolescent and, 65
  interventions, cost-effectiveness per life year gained, 9
  obesity and, 14

Insurance coverage, cardiac rehabilitation and, 9

Lactate threshold, hyperoxic gas and, 114
LDL. *See* Low-density lipoprotein
Letter to Editor, 239
Lifestyle modification, obesity in coronary patients and, 14
Lipids
  cardiac rehabilitation and, 394
  lowering in coronary artery disease, pravastatin and, 445
  management, coronary artery atherosclerosis and, 262
  preadolescent children and, physical fitness, physical activity, fatness and, 122
Littmann Cardiology II stethoscope, 80
Lovastatin, for hypercholesterolemia, cost-effectiveness per life year gained, 9
Low-density lipoprotein (LDL)
  chemical composition, exercise training and, 150
  monounsaturated fats and, 179
Lung disease, obstructive, single-lung transplantation and, 152
Lung transplantation, single, end-stage obstructive lung disease and, 152
Lyon Diet Heart Study, 179

Medical Manager, 306
Mediterranean diet, cardiovascular disease and, 179
M-HART. *See* Montreal Heart Attack Readjustment Trial
Mini-Logger Series 2000, 457
Minority adolescent, health promotion and, 65
Minute ventilation, gas exchange in heart disease and, 257
Mitral valve replacement (MVR), oxygen uptake and, exercise training and, 424
Montreal Heart Attack Readjustment Trial (M-HART), 103
Muscular strength training, elderly and, 283
MVR. *See* Mitral valve replacement
Myocardial infarction
  convalescent period, exercise training and, 269
  depression and, 297
  interventions, cost-effectiveness per life year gained, 9
  posthospital survival, gender differences, 150
  progressive and constant load work after, oxygen uptake and cardiac output and, 216
  psychosocial factors and, 103
  suspected, exercise testing and, 233
Myocardial ischemia, coronary artery disease and, physical fitness and, 431

Nasal cannula, oxygen therapy and, 299
National Pulmonary Rehabilitation Survey, 197
New Products and Services, 80, 158, 241, 305, 457
Nicotine, progression of coronary artery disease and, 47
Nutrition, 418

Obesity
  adolescent and, 65
  coronary patients and, treatment, 14
Obstructive lung disease, end-stage, single-lung transplantation and, 152
Outcome measurement, 394
Oxygen consumption, transplanted heart and, 288
Oxygen therapy, pulse and continuous flow, 299
Oxygen uptake
  gas exchange in heart disease and, 257
  post-aortic/mitral valve surgery, exercise training and, 424
  progressive and constant work load after acute myocardial infarction and, 216

PATH. *See* Patient's Attitudes Toward Health
Patient's Attitudes Toward Health (PATH), 130
Physical activity
  assessment, Caltrac accelerometer and, 107
  blood pressure and lipids in preadolescent children and, 122
Physical fitness
  blood pressure and lipids in preadolescent children and, 122

transient myocardial ischemia in coronary artery disease and, 431
PLB. *See* Pursed lip breathing
Portable aerobics stepper, 81
Portable emergency cardiac unit, 80
Pravastatin
coronary vasomotion in hypercholesterolemia and, 149
lipid lowering in coronary artery disease and, 445
Preadolescent, blood pressure and lipids and, physical fitness, physical activity, fatness and, 122
Progressive load work, after acute myocardial infarction, oxygen uptake and cardiac output and, 216
Propranolol, for hypertension, cost-effectiveness per life year gained, 9
Protein metabolism, beta-blockers and, 183
Pulmonary Abstract Reviews, 12, 76, 235, 299, 447
Pulmonary disease, chronic obstructive. *See* Chronic obstructive pulmonary disease
Pulmonary rehabilitation
adherence and, 420
exercise capacity of elderly patient and, 447
national survey, 406
outcome measurement, 394
outpatient, dyspnea and, 76
patient, cardiac rehabilitation patient compared, 277
randomized controlled trial, 235
regional survey, 197
Pulmonary rehabilitation professional, clinical competency guidelines, 173
Pursed lip breathing (PLB), chronic obstructive pulmonary disease and, 25
Quality of life
cardiac rehabilitation and, 143, 209, 394
gender differences, 225
chronic obstructive pulmonary disease and, short-form questionnaire and, 447
chronic obstructive pulmonary disease rehabilitation and, 152
pulmonary rehabilitation and, 394
Quality of Life Index–Cardiac Version, 143

Rate-pressure product (RPP)
at rest, 19
at submaximal exercise, 19
Rebounding exercise, cardiorespiratory fitness and, 34
REGRESS. *See* Regression Growth Evaluation Statin Study
Regression Growth Evaluation Statin Study (REGRESS), 445
Rehabilitation cardiac. *See* Cardiac rehabilitation
pulmonary. *See* Pulmonary rehabilitation
Respiratory rehabilitation, randomized controlled trial, 235
Resting energy expenditure, beta-blockers and, 183
Risk factors, coronary artery disease, 439
RPP. *See* Rate-pressure product

SCRIP. *See* Stanford Coronary Risk Intervention Project
Second-hand smoke, arteriosclerotic plaque development and, 233
Self-efficacy, cardiac rehabilitation and, 209
SensorMedics 2100 Pulmonary Function system, 130
Short Fat Questionnaire, 39
Sickness Impact Profile (SIP), 225
Single-lung transplantation (SLT), end-stage obstructive lung disease and, 152
SIP. *See* Sickness Impact Profile
SLT. *See* Single-lung transplantation
SmartDocs, 242
Smoking
intervention following coronary artery bypass surgery and, 39
progression of coronary artery disease and, 47
Smoking cessation
cardiac rehabilitation and, 394
cost-effectiveness per life year gained, 9
Spirometer, stand-alone, 241
Stair climbing
claudication patient and, 134
estimation of ventilatory reserve and, 76
Stand-alone spirometer, 241
Stanford Coronary Risk Intervention Project (SCRIP), 74
Stethoscope, dual frequency, 80
Strength training, elderly and, 283

Thallium scintigraphy, exercise testing and, 47
Transplanted heart, kinetics, 288
Transtracheal catheter, oxygen therapy and, 299
Triglycerides, monounsaturated fats and, 179

Ultralite ABP monitor, 241
Universal access, cardiac rehabilitation and, 9
Upper body exercise, chronic obstructive pulmonary disease and, 130

VacuMed CATEYE Heartbeat Counter, 81
Ventilatory reserve, estimation by stair climbing, 76
Ventilatory threshold (VT), gas exchange in heart disease and, 257
Ventricular fibrillation, recurrent cardiac events in survivors, implications for driving restrictions, 73
Ventricular tachycardia, recurrent cardiac events in survivors, implications for driving restrictions, 73
VT. *See* Ventilatory threshold

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970; Section 3685, Title 39 United States Code) Date of Filing—October 1, 1995. Title of Publication—Journal of Cardiopulmonary Rehabilitation; Frequency of Issue-Bimonthly; Annual Subscription Price—$69.00, Location of Known Office of Publication–12107 Insurance Way, Suite 114, Hagerstown, MD 21740; Location of the Headquarters of General Business Offices of the Publisher—Lippincott–Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Publisher-Lippincott–Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Editor—Barry A. Franklin, PhD, Journal of Cardiopulmonary Rehabilitation, 7611 Elmwood Ave., Suite 201, Middleton, WI 53562; Managing Editor—Lisa Nelson,7611 Elmwood Ave., Suite 201, Middleton, WI 53562; Owner—Lippincott–Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—Wolters Kluwer, US Corp.,1185 Avenue of the Americas, 37th floor, New York, NY 10036. A. Total no. copies printed (*net press run*), average 5,100, actual 6,600; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 4,019, actual 4,224; C. Total paid circulation, average 4,019, actual 4,224; D. Free distribution by mail carrier or other means. Samples complimentary, and other free copies, average 149, actual 144; E. Total distribution (*Sum of C and D*), average 4,435, actual 5,943; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 665, actual 657. 2. Returns from news agents, none; G. Total (*Sum of E & F—should equal net press runs shown in A*), average 5,100, actual 6,600. I certify that the statements made by me above are correct and complete. Virginia B. Martin, *Vice President, Operations.*